FirstWord
FirstWord belongs to a business group that forms one of the world’s largest healthcare knowledge networks. By tapping into its rich resources, FirstWord Dossier reports provide insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date and actionable intelligence … reports that deliver information vital for competitive advantage.
... grow from $3.5 billion in 2012 to $7.3 billion in 2017. Consensus Outlook: Prostate Cancer analyses the global prostate cancer market players and products of today ... market parameters including market size, product sales, market shares and competitive status over the period 2007 to 2017 Forecast and analysis ...
Apr, 2013... extensive analysis from experts in many fields to predict the top 10 Pharma companies in 2017. To stay ahead of your competition, you need to have the ... bank and equity research, analyst briefings, news sources, and company publications – to bring you consensus forecasts, insightful, in-depth analysis, and ...
Mar, 2013 223 pages... and health payer concerns about the high cost of treatment. Competition in the major segments of prostate cancer are set to intensify, with new hormone drugs, ... experience. Our unique KOL scoring system identifies those thought-leaders with the greatest insight into how Prostate Cancer clinical research will ...
Mar, 2013 135 pages... analysis of the trends which are shaping its development. Biosimilars in Emerging Markets is a 2-volume report which provides both a comprehensive overview of the ... over safety and quality. Volume 2 brings together highly-detailed market analysis with contributions from local industry experts whose clear ...
Mar, 2013 226 pages... also be overwhelming. FirstWord’s up-to-the-minute report on physician communities – Digital Doctors: Marketing to Online Networks (2nd Edition) – is your definitive guide to the ... ? How critical is the mobile dimension? Why did the US subsidiary of Japan’s M3 buy Doctors.net.uk, and what does that mean for ...
Mar, 2013 52 pages... apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs has the ... Editor, iMedicalApps and member, Steering Committee, Johns Hopkins Global mHealth Initiative Scott Morrison, Vice President, Information Systems, Boehringer Ingelheim ...
Feb, 2013 83 pages... Pharma do to maximise the credibility and visibility of its products? Overview The Path to Product Inclusion in Clinical Guidelines: Strategies for Success If you ... defining the clinical need around which you need to design your future products.” Charlie Buckwell, chief executive, McCann Complete Medical
Feb, 2013 49 pagesYour step-by-step guide to adapting to real time change. Over the past decade, closed loop marketing (CLM) has been a buzzword in pharma ... , continuous change to marketing and opportunities created by robust CLM. The report offers real-life experiences and best practices with companies who have actually ...
Jan, 2013 59 pages... ? This report will be of value to anyone involved emerging market development, particularly those with responsibilities in the following areas: Brand marketing and ... leader for a top five multinational company Marc Yates, director of emerging markets, Research Partnership Key Quotes: 'You know you have ...
Jan, 2013 94 pages... and biotech Uses for big data in pharma and biotech marketing Lessons from other industries Challenges facing those wanting to use ... of biomedical informatics at Mount Sinai School of Medicine Duncan Ross, director of data science at Teradata Jan-Eric Litton, professor, department of medical epidemiology ...
Jan, 2013 76 pages... exposure? This timely new report will help anyone in the publications field discover ways to tackle new challenges and maximise new ... their experiences exclusively with FirstWord, including Gary Evoniuk, director of publication practices at GlaxoSmithKline, who talks candidly about GSK’s recent announcement ...
Dec, 2012 57 pages... introduction more effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C analyses the global HCV market players and ... results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections ...
Dec, 2012... help pharma companies answer these critical questions. REPORT OVERVIEW The Rise of Health Outcome Liaison Teams At last – a practical guide to building your ... HOL strategy. This comprehensive report explains what is driving the rise of HOLs globally, and provides detailed accounts of how major pharma ...
Nov, 2012 86 pages... consumers themselves are able to express concerns online. The influence of social media on pharma marketing is such that even the largest and most ... looks at leading-edge activities such as data mining, investigates the future of mobile access, outlines legislative and regulatory efforts worldwide and offers ...
Nov, 2012 94 pages... market. Key Benefits Hepatitis C: the race for the first interferon-free regimen examines the most prominent insights gained from ... markets in other countries. In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific ...
Nov, 2012 246 pages... will learn how to capitalise on those opportunities. Report Overview Advisory Committees and Speaker Bureaux – Ensuring Compliance With the Sunshine Act due to ... – detailing how a major pharma company manages its physician advisory boards and speaker programmes, how a major medical centre determines what ...
Oct, 2012 74 pages
